A slow-release dexamethasone implant for cancer-associated retinopathy

This case report aims to show the anatomical and functional results of a patient diagnosed as having cancer-associated retinopathy treated with a controlled-release dexamethasone implant (Ozurdex). Anatomical outcomes were assessed using spectral domain optical coherence tomography; and functional outcomes, by measuring visual acuity, microperimetry, and mutifocal electroretinography. The follow-up period was 1 year.

Keywords:
Retinopathy; Dexamethasone; Paraneoplastic ocular syndromes; Electroretinography

Authorship

Leandro J. Chaves

Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, BrazilUniversidade de São PauloBrazilRibeirão Preto, SP, BrazilDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

https://orcid.org/0000-0001-6865-4949

Marina L. de Albuquerque

https://orcid.org/0000-0002-6931-4273

Amanda Schnorr

Francyne Cyrino

https://orcid.org/0000-0002-1892-6210

Maria Lúcia Habib

https://orcid.org/0000-0001-5331-903X

André Messias

https://orcid.org/0000-0002-5328-9608

Zelia M. Correa

Ocular Oncology Service, Bascom Palmer Eye Institute and Sylvester Cancer Center, University of Miami, Miami, FL, USAUniversity of MiamiUSAMiami, FL, USAOcular Oncology Service, Bascom Palmer Eye Institute and Sylvester Cancer Center, University of Miami, Miami, FL, USA

https://orcid.org/0000-0003-2946-3757

Rodrigo Jorge Corresponding author: Rodrigo Jorge. E-mail: retinausp@gmail.br

https://orcid.org/0000-0002-2652-0720

Corresponding author: Rodrigo Jorge. E-mail: retinausp@gmail.br

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose.

SCIMAGO INSTITUTIONS RANKINGS

Figures

Figures (2)

Thumbnail

Figure 1.
Baseline multimodal assessment. (A, B) An unremarkable color fundus retinography finding. (C, D) Spectral domain optical coherence tomography image showing the granular aspects of the inner and outer segment layers and ellipsoid zone. (E, F) Baseline microperimetry sensitivity map is abnormal in both eyes. (G, H) Multifocal electroretinogram trace array showing an abnormal asymmetrical reduction in central response in both eyes.

Thumbnail

Figure 2.
Clinical outcome 30 days after insertion of the controlled-release dexamethasone implant in the left eye. (A) Spectral domain optical coherence tomography (OCT) image showing no changes in the right eye. (B) Spectral domain OCT image showing partial recovery of the inner and outer segment layers and ellipsoid zone of the left eye. (C, D) Microperimetry sensitivity maps showing abnormal macular integrity especially in the left eye, although it is an improvement from that at baseline. (E, F) Abnormal multifocal electroretinogram trace array in both eyes, showing an asymmetrical reduction in central response.

Figure 1. Baseline multimodal assessment. (A, B) An unremarkable color fundus retinography finding. (C, D) Spectral domain optical coherence tomography image showing the granular aspects of the inner and outer segment layers and ellipsoid zone. (E, F) Baseline microperimetry sensitivity map is abnormal in both eyes. (G, H) Multifocal electroretinogram trace array showing an abnormal asymmetrical reduction in central response in both eyes.

Figure 2. Clinical outcome 30 days after insertion of the controlled-release dexamethasone implant in the left eye. (A) Spectral domain optical coherence tomography (OCT) image showing no changes in the right eye. (B) Spectral domain OCT image showing partial recovery of the inner and outer segment layers and ellipsoid zone of the left eye. (C, D) Microperimetry sensitivity maps showing abnormal macular integrity especially in the left eye, although it is an improvement from that at baseline. (E, F) Abnormal multifocal electroretinogram trace array in both eyes, showing an asymmetrical reduction in central response.

How to cite

copy

Conselho Brasileiro de Oftalmologia Rua Casa do Ator, 1117 - cj.21, 04546-004 São Paulo SP Brazil, Tel: 55 11 - 3266-4000, Fax: 55 11- 3171-0953 - São Paulo - SP - Brazil
E-mail: abo@cbo.com.br

Acompanhe os números deste periódico no seu leitor de RSS

Versão para download de PDF

PDF

Inglês

Versões e tradução automática

Versão original do texto

English

Tradução automática

Google Translator
Microsoft Translator

Como citar

RIS

BIBTEX

Outros formatos de citação e exportação:

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
E-mail: scielo@scielo.org

Leia a Declaração de Acesso Aberto

Métricas

A slow-release dexamethasone implant for cancer-associated retinopathy

PlumX

Mensagem

[1] Corresponding author: Rodrigo Jorge. E-mail: retinausp@gmail.br